PT2993983T - Corroles direcionados para toxicidade tumoral e imagiologia por ressonância magnética - Google Patents

Corroles direcionados para toxicidade tumoral e imagiologia por ressonância magnética

Info

Publication number
PT2993983T
PT2993983T PT147944102T PT14794410T PT2993983T PT 2993983 T PT2993983 T PT 2993983T PT 147944102 T PT147944102 T PT 147944102T PT 14794410 T PT14794410 T PT 14794410T PT 2993983 T PT2993983 T PT 2993983T
Authority
PT
Portugal
Prior art keywords
mri
tumor toxicity
corroles
targeting
targeting corroles
Prior art date
Application number
PT147944102T
Other languages
English (en)
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of PT2993983T publication Critical patent/PT2993983T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT147944102T 2013-05-08 2014-05-08 Corroles direcionados para toxicidade tumoral e imagiologia por ressonância magnética PT2993983T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361821106P 2013-05-08 2013-05-08

Publications (1)

Publication Number Publication Date
PT2993983T true PT2993983T (pt) 2020-05-22

Family

ID=51864925

Family Applications (1)

Application Number Title Priority Date Filing Date
PT147944102T PT2993983T (pt) 2013-05-08 2014-05-08 Corroles direcionados para toxicidade tumoral e imagiologia por ressonância magnética

Country Status (17)

Country Link
US (2) US9757386B2 (pt)
EP (2) EP2993983B1 (pt)
JP (1) JP6640715B2 (pt)
KR (1) KR20160008523A (pt)
CN (2) CN108451930A (pt)
AU (2) AU2014262653B2 (pt)
CA (1) CA2910030A1 (pt)
DK (1) DK2993983T3 (pt)
ES (1) ES2791043T3 (pt)
HK (1) HK1221870A1 (pt)
IL (1) IL265935B (pt)
MX (1) MX2015015434A (pt)
PL (1) PL2993983T3 (pt)
PT (1) PT2993983T (pt)
RU (1) RU2674146C2 (pt)
WO (1) WO2014182868A1 (pt)
ZA (1) ZA201508092B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009009441A2 (en) 2007-07-06 2009-01-15 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
PL2880160T3 (pl) 2012-08-03 2019-03-29 Cedars-Sinai Medical Center Izolowanie wzmacniających transport mutantów białka dostarczającego lek
MX2015015434A (es) 2013-05-08 2016-03-15 Cedars Sinai Medical Center Corroles dirigidas para toxicidad tumoral y rm.
BR112016016202A2 (pt) 2014-01-17 2017-09-19 Cedars Sinai Medical Center Construtos de direcionamento de receptores e uso dos mesmos
EP3129066B1 (en) 2014-04-04 2020-08-12 Cedars-Sinai Medical Center Targeting trastuzumab-resistant her2+breast cancer with a her3-targeting nanoparticle
WO2019043711A1 (en) * 2017-08-31 2019-03-07 Technion Research & Development Foundation Limited COMPOSITIONS OF CORROLE

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA129822A (en) 1910-08-24 1910-12-13 The John Bertram And Sons Company, Limited Motor controlling apparatus
CA140995A (en) 1912-03-05 1912-06-11 Davydd C. Hughes Type plate mechanism
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
WO2002094318A1 (en) 2001-05-18 2002-11-28 University Of Southern California Vector for targeted delivery to cells
WO2003004021A1 (en) * 2001-07-02 2003-01-16 Technion Research And Development Foundation Ltd. Method for the preparation of selectively-substituted corroles and new substituted corroles
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
WO2009009441A2 (en) 2007-07-06 2009-01-15 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
WO2009027965A1 (en) * 2007-08-28 2009-03-05 Technion Research And Development Foundation Ltd. Transition metal complexes of corroles for preventing cardiovascular diseases or disorders
EP2244701B1 (en) * 2008-01-31 2012-05-09 Technion Research and Development Foundation, Ltd. Corroles for neuroprotection and neurorescue
WO2009151539A1 (en) 2008-05-24 2009-12-17 Sirnaomics, Inc. COMPOSITIONS AND METHODS USING siRNA MOLECULES FOR TREATMENT OF GLIOMAS
US9012622B2 (en) 2008-12-31 2015-04-21 Patrick Y. Lu Compositions and methods using siRNA molecules and siRNA cocktails for the treatment of breast cancer
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
CN101704820A (zh) * 2009-09-24 2010-05-12 江苏大学 三(4-氯苯基)咔咯化合物及其合成方法
WO2011094335A2 (en) 2010-01-26 2011-08-04 Yale University Microrna signatures predicting responsiveness to anti-her2 therapy
MX2014001823A (es) * 2011-08-15 2014-08-21 Technion Res & Dev Foundation Combinaciones de corroles y estatinas.
PL2880160T3 (pl) 2012-08-03 2019-03-29 Cedars-Sinai Medical Center Izolowanie wzmacniających transport mutantów białka dostarczającego lek
MX2015015434A (es) 2013-05-08 2016-03-15 Cedars Sinai Medical Center Corroles dirigidas para toxicidad tumoral y rm.
BR112016016202A2 (pt) 2014-01-17 2017-09-19 Cedars Sinai Medical Center Construtos de direcionamento de receptores e uso dos mesmos
EP3129066B1 (en) 2014-04-04 2020-08-12 Cedars-Sinai Medical Center Targeting trastuzumab-resistant her2+breast cancer with a her3-targeting nanoparticle
KR20190013929A (ko) 2016-05-27 2019-02-11 세다르스-신나이 메디칼 센터 약물-전달 나노입자 및 약물 내성암에 대한 치료

Also Published As

Publication number Publication date
EP3730155A1 (en) 2020-10-28
AU2018250401A1 (en) 2018-11-08
IL265935A (en) 2019-05-30
CA2910030A1 (en) 2014-11-13
US20170281802A1 (en) 2017-10-05
IL265935B (en) 2020-06-30
DK2993983T3 (da) 2020-05-18
PL2993983T3 (pl) 2020-09-07
EP2993983B1 (en) 2020-03-25
KR20160008523A (ko) 2016-01-22
WO2014182868A1 (en) 2014-11-13
US9757386B2 (en) 2017-09-12
US10709801B2 (en) 2020-07-14
AU2018250401B2 (en) 2020-06-11
CN105307499B (zh) 2018-04-27
JP6640715B2 (ja) 2020-02-05
EP2993983A1 (en) 2016-03-16
CN108451930A (zh) 2018-08-28
CN105307499A (zh) 2016-02-03
ZA201508092B (en) 2017-02-22
HK1221870A1 (zh) 2017-06-16
JP2016526021A (ja) 2016-09-01
AU2014262653B2 (en) 2018-07-26
AU2014262653A1 (en) 2015-11-12
RU2015152033A3 (pt) 2018-04-25
RU2674146C2 (ru) 2018-12-07
ES2791043T3 (es) 2020-10-30
EP2993983A4 (en) 2017-01-11
MX2015015434A (es) 2016-03-15
US20140335025A1 (en) 2014-11-13
RU2015152033A (ru) 2017-06-16

Similar Documents

Publication Publication Date Title
IL265935B (en) Targeting corroles for tumor toxicity and MRI
HK1219981A1 (zh) 癌症中靶向
HK1219658A1 (zh) 吡咯並苯並二氮雜卓及其結合物
HK1219651A1 (zh) 吡咯並苯並二氮雜卓以及其結合物
ZA201602501B (en) Pyrrolobenzodiazepines and conjugates thereof
HK1214140A1 (zh) 吡咯並苯並二氮雜卓和其結合物
ZA201505735B (en) Cancer drug and uses
GB201317981D0 (en) Pyrrolobenzodiazepines and conjugates thereof
GB2513596B (en) Image-guided radiotherapy
GB201322725D0 (en) Cancer therapy
HK1220900A1 (zh) 癌症的治療
EP2974879A4 (en) DISPLAY ELEMENT
SG11201507847UA (en) Cancer therapy
GB201317367D0 (en) Magnetic stimulator arrangement
EP3052888A4 (en) INTEGRATED BODY PROTECTIVE CLOTHING PIECE
EP3044590A4 (en) Methods and compositions for tumor vasculature imaging and targeted therapy
EP2971682A4 (en) INTEGRATED FLEXIBLE CARRIER AND FRONT / CENTER BODY
EP2961412A4 (en) CANCER THERAPY
PL3068797T3 (pl) Konstrukty wielowalentnego celowania w nowotwory
GB201307269D0 (en) Combination Therapy
EP2896692A4 (en) CANCER MARKERS AND APPLICATION THEREOF
GB201308039D0 (en) Photodynamic therapy
EP2965697A4 (en) INTRA-ORDINARY INTRODUCTION INSTRUMENT
GB201316666D0 (en) Targeting molecule
GB201317213D0 (en) Cancer Therapy